ClinicalTrials.gg
RecruitingNCT05971329Updated Apr 24, 2025

Pilot Study of ZetaFuse™ Bone Graft for the Treatment of Cervical Degenerative Disc Disease

An interventional study of Cervical Fusion (ZetaFuse™ Bone Graft) in Radiculopathy, Cervical, Myelopathy Cervical and Neurological Abnormality, sponsored by Zetagen Therapeutics, Inc. Recruiting at 2 sites in Australia. Open to participants aged 22 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Zetagen Therapeutics, Inc · Not applicable, Interventional, and Device feasibility

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
All
01

Study summary

The goal of this pilot clinical trial is to test the safety and preliminary performance of the ZetaFuse Bone Graft in patient requiring fusion of the C3-C7 vertebral bones due to pain or loss of neurological function.

Participants will be treated with ZetaFuse during surgical intervention to reduce pain and the loss of neurological function.

Read the detailed description

The indication under investigation is for use in the skeletally mature patients for fusion of one or two contiguous vertebral bodies in the cervical spine from C3-C7 following discectomy for intractable radiculopathy with or without neck pain, or myelopathy due to abnormality localized to the disc space and manifested by at least one of the following conditions confirmed by radiographic imaging:herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels.

02

Conditions studied

  • Radiculopathy, Cervical
  • Myelopathy Cervical
  • Neurological Abnormality
  • Disc Disease
  • Disc Degeneration
03

In context

Radiculopathy

488 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 375 interventional studies indexed under Radiculopathy.

Browse Radiculopathy studies →

Lead sponsor

Zetagen Therapeutics, Inc is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 22 to 75 years (inclusive) at the time of enrollment.
  2. Diagnosis of radiculopathy and/or myelopathy of the cervical spine, with pain, paresthesias or paralysis in a specific nerve root distribution C3 through C7, including at least one of the following:

    • Neck and/or arm pain (at least 3 on the 0 - 10 numeric rating scale for pain.
    • Decreased muscle strength of at least one level on the clinical evaluation 0 to 5 scale.
    • Abnormal sensation including hyperesthesia or hypoesthesia. and/or
    • Abnormal reflexes.
  3. Symptomatic at one or two contiguous levels from C3 to C7.
  4. Radiographically determined pathology at the level to be treated correlating to primary symptoms including at least one of the following:

    • Decreased disc height on radiography, computed tomography (CT), or magnetic resonance imaging (MRI) in comparison to a normal adjacent disc.
    • Degenerative spondylosis on CT or MRI.
    • Disc herniation on CT or MRI.
  5. Neck Disability Index Score ≥ 30/100.
  6. Unresponsive to non-operative treatment (e.g., rest, heat, physical therapy, chiropractor, massage, pain medication) for approximately six weeks from the symptom onset; or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative management.
  7. No previous surgical intervention at the involved levels or any subsequent, planned/staged surgical procedure at the involved or adjacent levels.
  8. Appropriate for treatment using an anterior surgical approach.
  9. Skeletally mature at the time of the surgery.
  10. Medically cleared for surgery.
  11. If a female of , subject is non-pregnant, nonnursing, and agrees not to become pregnant during the study period.
  12. Willing and able to comply with the study plan.
  13. Signed written Patient Form.
  14. Willing to discontinue use of non-steroidal anti-inflammatory drugs (NSAIDs) from one week before the surgery to 3 months after the surgery.

Exclusion criteria

Exclusion Criteria:

  1. A cervical spinal condition other than symptomatic cervical degenerative disc disease requiring surgical treatment at the involved levels.
  2. Documented or diagnosed cervical instability relative to adjacent segments at either level, defined by dynamic (flexion/extension) radiographs showing sagittal plane translation >3.5 mm or sagittal plane angulation > 20°.
  3. More than two cervical levels requiring surgical treatment.
  4. An immobile or spontaneously fused level adjacent to the levels to be treated.
  5. Severe pathology of the facet joints of the involved vertebral bodies.
  6. Previous surgical intervention at either one or both of the involved levels or at adjacent levels.
  7. History of trauma to the C3 to C7 levels resulting in significant bony or disco-ligamentous cervical spine injury.
  8. Previously diagnosed with osteomalacia;
  9. Any of the following that may be associated with an increased risk osteoporosis (if "Yes" to any of the below risk factors, a DEXA Scan is required to determine eligibility). If the level of bone mineral density (BMD) on DEXA scan is a T score of -2.5 or worse (i.e., -2.6, - 2.7, etc.) the subject is ineligible for the study.

    • non-Black female over 60 years of age who weighs less than 140 pounds.
    • Postmenopausal female who has sustained a non-traumatic hip, spine, or wrist fracture.
    • Male over the age of 60 who has sustained a non-traumatic hip or spine fracture.
    • Taking bisphosphonate medication for the treatment of osteoporosis.
    • Chronic use of high dose .
  10. Reported active that included a history of any invasive malignancy (except non-melanoma skin cancer) unless the subject had been treated with curative intent and there had been no clinical signs or symptoms of the malignancy for at least five years.
  11. Overt or active systemic infection, or infection at the operative site.
  12. Insulin dependent diabetes.
  13. A tobacco user who does not agree to suspend smoking prior to surgery.
  14. Chronic or acute renal failure or prior history of renal disease.
  15. Mentally incompetent (If questionable, obtain psychiatric consult).
  16. A prisoner.
  17. An alcohol and/or drug abuser currently or recently undergoing treatment for alcohol and/or drug abuse.
  18. Involved with current or pending litigation regarding a spinal condition.
  19. Received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate) excluding routine perioperative anti-inflammatory drugs.
  20. A history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers- Danlos Syndrome, or osteogenesis imperfecta).
  21. A condition that requires post-operative medications that interfere with the stability of the implant, such as steroids. (This does not include low dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs).
  22. Received treatment with an therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation with the ZetaFuse™ Bone Graft device.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Pilot Study of ZetaFuse Bone Graft for the Treatment of Cervical Degenerative Disc Disease

    Involves the use of a medical device. The prepared ZetaFuse Bone Graft is packed into the hollow space of a PEEK interbody before surgical implantation.

    Device: Cervical Fusion (ZetaFuse™ Bone Graft)

Interventions

  • DeviceCervical Fusion (ZetaFuse™ Bone Graft)

    Fusion of the C3-C7 cervical vertebral bodies

06

What researchers measure

Primary outcomes

  1. Subjects with Radiologic Determination of Bone Fusion of the Treated Cervical Vertebral Bones

    Radiological Fusion of the cervical vertebral bones, assessed using planar X-radiographs or computed tomography. Fusion is defined as continuous bridging bone between the endplates of the operated cervical vertebral bones. Subjects with fusion will be assessed as having a successful outcome while subjects without fusion will have failed the procedure.

    Time frame: 1 year post surgery

Secondary outcomes

  1. Quality of Life via Short Form (SF12v2) Health Survey

    SF12 measures quality of life, pain, and activity in a survey using 12 questions, with scores \>50 showing a better outcome

    Time frame: 1 year post surgery

07

Study locations

2 of 2 sites recruiting
  • Prince of Wales Private Hospital
    Randwick, New South Wales 2031, Australia
    Recruiting
  • Prince of Wales Public Hospital
    Randwick, New South Wales 2031, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2026, 0 months later.

Of 217 interventional studies with no phase under Radiculopathy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 41. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Aug 2, 2023
StartEst.
Sep 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2027
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05971329
Lead sponsor
Zetagen Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 2, 2023
Start date
Sep 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Apr 24, 2025

Study contacts

Julie Croft
Contact
julie.croft@avancecro.com
0882494788

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion